Introducing a selection of ovarian and breast cell lines, small molecules used in prostate cancer therapeutics, cytokines, peptides and NOD1 knock out cell lines as well as a range of different antibodies and fluorescent markers.

It’s been a challenging few months since the global spread of the Coronavirus pandemic, but those laboratories that didn’t stay open to focus on the virus, are starting to reopen with researchers able to return to their laboratories. Like many other Technology Transfer Offices (TTOs), we’ve been working as normally as we possibly can with reduced staff capacity and working hours. However, we’ve been delighted to still be forming new partnerships and adding new tools to our portfolio. We now have over 150 partnerships across 6 continents. Here are some of our newest partners and latest research tools:


A new partnership with the University of Ilorin, in Nigeria, had led to the addition of two new vectors: pCRBLUNT-HBsAg Vector and pGEM-β-globin Vector. pCRBLUNT-HBsAg Vector targets Hepatitis B surface antigens and was designed as a positive control for diagnostic applications. pGEM-β-globin Vector is ampicillin resistant and targets human β-globin. It is designed as a positive control for molecular studies.


New partnerships with institutions in Israel have been established including Tel Aviv University (Ramot) and Hadassah Medical Centre (Hadasit). New research tools from these institutions include:

  • A series of prostate cancer cell lines from Weizmann Institute of Science: These cell lines support the study of prostate cancer by presenting an in vitro model system, enabling the study of human prostate cell differentiation and malignant transformation and supporting the understanding of biological behaviour of CAFs in cells. 
  • A group of ovarian and breast cancer cell lines from Hadassah Medical Center and Rambam Health Care Campus: These breast cell lines can serve as a platform for drug screening for cancer stem cells targeted compounds in vitro and in vivo.
  • A range of fluorescent markers for the endoplasmic reticulum (ER) of live pathogenic fungal cells from Ramot - Tel Aviv University: The ER is the site of action of antifungal azole drugs, used as a first-line treatment for fungal infections. 

A small molecule from Osaka University has recently been added to the portfolio. This conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells.


The first Ximbio-New Zealand partnership has recently been established with the University of Auckland. New research tools from this institute will be added to the portfolio shortly. Several of our Australian Technology Transfer partners have added new research tools to our portfolio. These include:

Europe and the UK

Several new partnerships have been established recently across Europe including the University of Tartu in Estonia, I&I Prague and Institute of Biotechnology Prague (IBT) in the Czech Republic and Toulouse Tech Transfer (SATT) in France. New research tools from our European partnerships include:

North America

Our network of partners in North America has expanded to include a number of new Technology Transfer Offices including the University of Miami, the Puerto Rico Science, Technology & Research Trust, Rush University Medical Center and the University of North Texas. Several new research tools have also been added to the portfolio:

South America

We are proud to announce a new partnership with Pontificia Universidad Catolica de Chile. New research tools from this Institute will be added to the portfolio shortly.

Although there is a lot of uncertainty at the moment, we will be continuing to add new partners and research tools to our portfolio. If you are interested in any of the products, or research areas listed above, please don’t hesitate to get in touch. Alternatively, if there is a particular research area you find of interest, please do let us know.